|
Adult Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In summary, this investigation identifies an EGFR-DOCK180-RAC1-MLK3-JNK signaling axis that drives glioblastoma cell migration and dissemination.<b>Implications:</b> On the basis of these findings, MLK3 emerges as a potential therapeutic target for the treatment of glioblastoma.<i></i>.
|
28487380 |
2017 |
|
Arthritis, Gouty
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study of clinically defined gout identifies multiple risk loci and its association with clinical subtypes.
|
25646370 |
2016 |
|
Blood basophil count (lab test)
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease.
|
27863252 |
2016 |
|
Brain Ischemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
Based on the facts that MLK3 is one client protein of HSP90 and MLK3 pathway induces FasL expression in ischemic brain injury, our study suggests one of the mechanisms of neuroprotection against brain ischemia from GA.
|
28522336 |
2017 |
|
Brain Ischemia
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
We also investigated whether the activation of MLK3 is associated with S-nitrosylation following rat brain ischemia/reperfusion.
|
22123824 |
2012 |
|
Breast Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that mammalian PAK1 does not act as a MAP4K and MLK3-induced direct activation of PAK1 plays a key role in breast cancer tumorigenesis.
|
30664689 |
2019 |
|
Breast Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
To assess MLK3's contribution to the breast cancer malignant phenotype in a more physiological setting, we implemented a strategy to inducibly express active MLK3 in the preformed acini of MCF10A cells grown in 3D Matrigel.
|
20514022 |
2010 |
|
Carcinogenesis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Thus, MLK-3 signaling affects numerous cellular processes, raising the possibility that MLK-3 might play a role in oncogenesis.
|
9187672 |
1997 |
|
Carcinogenesis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Mixed-lineage kinase 3 (MLK3), the mitogen-activated protein kinase kinase kinase (MAP3K), has been recognized as a player in tumorigenesis and oncogenic signalling, yet its detailed functions and signalling in cervical cancer have not been fully elucidated.
|
31192472 |
2019 |
|
Carcinogenesis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Correction: Mixed lineage kinase 3 promotes breast tumorigenesis via phosphorylation and activation of p21-activated kinase 1.
|
31530933 |
2020 |
|
Carcinogenesis
|
0.050 |
AlteredExpression
|
phenotype |
BEFREE |
These results suggest that mammalian PAK1 does not act as a MAP4K and MLK3-induced direct activation of PAK1 plays a key role in breast cancer tumorigenesis.
|
30664689 |
2019 |
|
Carcinogenesis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
These findings collectively suggest that the MLK3-Pin1 signaling cascade plays a critical role in regulating the cell cycle, centrosome numbers, and oncogenesis.
|
22566623 |
2012 |
|
Carcinoma
|
0.020 |
Biomarker
|
group |
BEFREE |
This review is focused on the molecular profile of alterations in members of the KRAS signaling pathway (EGFR, KRAS, BRAF, PIK3CA, RASSF1A, and MLK3 genes) in MSI gastrointestinal carcinomas.
|
21070916 |
2010 |
|
Carcinoma
|
0.020 |
GeneticVariation
|
group |
BEFREE |
MLK3 mutations were significantly associated with MSI phenotype in primary tumours (P = 0.0005), occurring in 21% of the MSI carcinomas.
|
19955118 |
2010 |
|
Cerebral Infarction
|
0.020 |
Biomarker
|
disease |
BEFREE |
S-nitrosylation of mixed lineage kinase 3 contributes to its activation after cerebral ischemia.
|
22123824 |
2012 |
|
Cerebral Infarction
|
0.020 |
Biomarker
|
disease |
BEFREE |
The potential role of HO-1 in regulating the MLK3-MKK7-JNK3 module scaffolded by JIP1 during cerebral ischemia/reperfusion in rats.
|
30412737 |
2019 |
|
Cerebrovascular accident
|
0.010 |
AlteredExpression
|
group |
BEFREE |
These data suggest that the activation of MLK3 during the early stages of ischemia/reperfusion is modulated by S-nitrosylation and provides a potential new approach for stroke therapy whereby the post-translational modification machinery is targeted.
|
22123824 |
2012 |
|
cervical cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results demonstrate the importance of MLK3 in cervical cancer progression via modulating the Notch-1/autophagy network, and suggest that MLK3 is a promising therapeutic target for cervical cancer.
|
31192472 |
2019 |
|
Cervix carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results demonstrate the importance of MLK3 in cervical cancer progression via modulating the Notch-1/autophagy network, and suggest that MLK3 is a promising therapeutic target for cervical cancer.
|
31192472 |
2019 |
|
Childhood Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In summary, this investigation identifies an EGFR-DOCK180-RAC1-MLK3-JNK signaling axis that drives glioblastoma cell migration and dissemination.<b>Implications:</b> On the basis of these findings, MLK3 emerges as a potential therapeutic target for the treatment of glioblastoma.<i></i>.
|
28487380 |
2017 |
|
Chronic Lymphocytic Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Together, this indicates that MAP3K11 might function as an important tumor suppressor neutralized by oncomiR-125b in B-cell leukemia.
|
26138442 |
2016 |
|
Colon Carcinoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, S705A-S758A-FLAG-MLK3 demonstrated decreased oxidative-stress induced colon cancer cell invasion, but increased interaction with GST-B-Raf as compared with wild-type-FLAG-MLK3 in H<sub>2</sub>O<sub>2</sub>-treated cells.
|
29084209 |
2018 |
|
Colon Carcinoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
DUSP2 rs1724120 [hazard rate ratio (HRR) = 0.72, 95%CI = 0.54, 0.96; AA versus GG/GA), MAP3K10 rs112956 (HRR = 1.40, 95% CI = 1.10, 1.76; CT/TT versus CC) and MAP3K11 (HRR = 1.76, 95% CI 1.18, 2.62 TT versus GG/GT) influenced survival after diagnosis with colon cancer; MAP2K1 rs8039880 (HRR = 2.53, 95% CI 1.34, 4.79 GG versus AG/GG) and Raf1 rs11923427 (HRR = 0.59 95% CI = 0.40, 0.86; AA versus TT/TA) were associated with rectal cancer survival.
|
23027623 |
2012 |
|
Colorectal Carcinoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
The results provide an overall view of the expression profile associated with mutant MLK3, and they support the functional role of mutant MLK3 by showing a deregulation of several signaling pathways known to play important roles in the development and progression of colorectal cancer.
|
24628919 |
2014 |
|
Colorectal Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In human colorectal carcinoma (HCT116) cells treated with H<sub>2</sub>O<sub>2</sub>, extracellular signal-regulated kinases 1 and 2 (ERK1/2) were activated and MLK3 exhibited reduced electrophoretic mobility (shift) in sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), which was eliminated by phosphatase treatment.
|
29084209 |
2018 |